Halozyme Therapeutics Incorporated (HALO) News

Query: Do you think it possible that Halozyme is simply selling the rhuph20 as a commodity without a partnership deal in order to encourage these trials with the hope that the companies will ultimately be induced to commit to a more traditional deal after seeing positive results?
In any event, thanks for sharing. We can keep our ears peeled the next CC for further references to these potential partnerships.

Great, at least Enhanze and Halozyme was mentioned twice, in a side note......

biotech....."What clues have seen you for Selatogrel being used with rhuph20?"

Absolutely none at all......But if you read a past post you would know Halo gets low to double digit for supplying the....AutoInjector... and...Packaging...the Selatogrel product.....of which thousands are being cranked out for the growing on going clinical trial...........around 10-14 percent royalties of a blockbuster product is worth at least mentioning on the website or in a presentation once in awhile......

See past post on a comment from an old ATRS presentation........"SUPPLY fully packaged product at cost plus margin and ROYALTIES escalating to low double digits".............which answer's Jeff's comment on Yahoo.......The AI business has huge potential if it could combine drug-rhuph20-AI-packaging for any of the blockbuster bio drugs......not low signal digits.....but mid-teen royalties.....

Fred...."In my opinion, if HALO has contracts with these companies, this is material information that must be disclosed to the general investing public."

They are both hidden in the corners of Halo documents, but terribly under reported in any Halo presentations..........

Halo involved in two products that have blockbuster potential, per both of the product companies, and not a peep from Halo.......Therefore a share price of 38 bucks......IMO....

Roche subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

04/17/2024 | Briefing.com
RHHBY

Roche announced today data from the Phase Ill
OCARINA Il study (S31.006) of OCREVUS (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treatment with OCREVUS SC led to rapid and sustained B-cell depletion in the blood. The data will be presented as an oral presentation at the 76th American Academy of Neurology (AAN) Annual Meeting taking place April 13-18 in Denver and has been recognised as an abstract of distinction by the AAN scientific committee. Updated, longer-term results showed that OCREVUS SC injection (920 mg; n=236; both treatment arms [OCR SC/SC and OCR IV/SC]) resulted in near-complete suppression of relapse activity (97.2% had no relapse during the treatment phase) and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing (T1 Gd+) lesions and no new/enlarging T2 lesions. These lesion types are markers of active inflammation and burden of disease, respectively.

What clues have seen you for Selatogrel being used with rhuph20?

What clues have seen for Selatogrel being used with rhuph20 ?

In my opinion, if HALO has contracts with these companies, this is material information that must be disclosed to the general investing public.

HC Wainwright analyst M. Kapoor reiterates BUY and $50 PT.

Interesting news on another under reported Halo connection….…..

Just like Halo’s silence on Selatogrel, with blockbuster potential (Viatris words), Halo is silent on Sabirnetug with similar block buster potential. Recent presentation by Acumen, and manufacturing deal with Lonza is very promising.

Price/Earnings Ratios:

2024 Estimates
11.63
2025 Estimates
9.31
2026 Estimates
6.83

Forecast 12 Month Forward PEG Ratio 0.47

https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

From Akos on Yahoo:

“J&J reports Q1 sales of darzalex , $2.692 billion up 18.9 percent year over year.
24q1. 2.692
23q4. 2.55
23q3. 2.49
23q2 2.43
23q1. 2.26”

Benchmark analyst R. Wasserman reiterates BUY with $50 PT.

Agreement!

Silence of the lambs… such is the the board. Strange to see a stock turn belly up in the face of so much earlier pumping. Assorted analysts and stock market prognosticators forever pumping; various biotechwhomevers pumping vigorously (when not busy chastising the CEO and IR person for undermining the Stock of Great Promise based on ratio analysis and other wonderful tools) “Gloom and Doom” heathen working to put in their word which is a sure-fire indicator we have been informed. All systems go. But, just look… Like the red tide sweeping into Florida waters: fish belly up. Bad time to go fishing.

Hmmmm… Come on “doom and gloom” brothers, a little more vigorous efforts, if you please. More gloom, Scotty, this thing needs help to achieve warp gains. We have pumpers on the starboard bow, life, yes…, but not as we know it, jinxing the good ship Halozyme. Oh, I almost forgot about the market tanking. Does THAT make any difference? Why? Are we in unfriendly territory, neutralizing the salutary doom and gloom efforts?

Agreed. Approval of Hytrulo for CIDP will help but we will likely need unexpected good news to get above $45.

I would add that the cup and handle formation is also a bullish indicator, FWIW. All I see, though is a stock locked in a very clear, definable pattern, and on the high end of that pattern at that; so, absent news, this is likely going to sag to the mid to low 30s IMHO.

Halozyme Therapeutics Inc forms bullish "Double Moving Average Crossover" chart pattern
Apr 08, 2024

Trading Central has detected a "Double Moving Average Crossover" chart pattern formed on Halozyme Therapeutics Inc (HALO:NASDAQ). This bullish signal indicates that the stock price may rise from the close of $39.91.

Tells Me: The price is generally in an established trend (bullish or bearish) for the time horizon represented by the moving average periods.

Moving averages (MA) are used to smooth out the volatility or "noise" in the price series, to make it easier to discover the underlying trend. By plotting the average price over the last several bars, the line is less "jerky" than plotting the actual prices. In the double crossover method, a bullish event is generated when a faster moving average crosses above a slower moving average (21-bar MA crosses 50-bar, or 50-bar MA crosses 200-bar). In this state, the price is likely in an established uptrend. The opposite is true when the faster slips below the slower moving average, triggering a bearish event.

This bullish pattern can be seen on the following chart and was detected by Trading Central proprietary pattern recognition technology.

I actually think the crossover happened today but the article is from yesterday. According to yahoo finance, the 50 is at $38.74 and the 200 at $38.66. Hopefully, some good news is around the corner.

https://finance.yahoo.com/quote/HALO/chart?nn=1#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--

Good Job, Helen!

The top 5 science research-related stocks in 2024, as of the latest data available, are:

Biomarin Pharmaceuticals Inc. (BMRN) - 43.0% 5-Year Average Annual EPS Forecast
Halozyme Therapeutics, Inc. (HALO) - 25.0% 5-Year Average Annual EPS Forecast
Incyte Corporation (INCY) - 22.5% 5-Year Average Annual EPS Forecast
Genmab AS (GMAB) - 19.7% 5-Year Average Annual EPS Forecast
Exelixis, Inc. (EXEL) - 19.0% 5-Year Average Annual EPS Forecast

These stocks were chosen based on their forecasted earnings growth over the next five years, with a focus on those expected to grow EPS by an average of at least 9.5% per year over the next five years.

Moderator?

There is adequate cash flow to service the current debt, in my opinion, but that is assuming the management does not make any bonehead moves to tie it up in other pursuits.

Defiinitely is subcu but I don't see any method of action listed in the documentation.

Is the debt level for Halo a big risk factor (e.g. in a setting where interest rates stay high for a long time, longer than the market currently thinks)?

I think it is subdermal shot given once to a total of 32 patients. I could very well be wrong.

No such deal has been made public to my knowledge. What makes you think they are using hyaluronidase?

Is HALO supplying Apogee for their P1 Apg808 copd/anti inflammatory trial?

I agree...EXCELLENT company & CEO!

https://www.nasdaq.com/articles/the-3-best-biotech-stocks-to-buy-in-q2-2024

Oh, go take a hike! Do you really believe I am going to scour the board for my old posts just to obey your frivolous quibbles? Do you realize how goofy you sound?I tell you this much, since I looked, the shares I bought below 34 I bought on 06/06/23. The ones I sold just below 40 I bought earlier, around the same price or less. Don’t worry, I have already settled with the IRS. If that isn’t enough for you, too bad.

OK, I looked. On 06/07/23 I posted:
“After posting my reservations about this company, many of which remain, I think it is only proper to note that yesterday I picked up some shares. I didn’t bet the farm, I don‘t do that any more on any stock, but did pick up a few thousand shares. I hope that the downside is limited, but I don’t know what my upside hopes are as the company has been utterly mute. Definitely not “to the Moon, Alice”. I expect to take half off the table in the mid 40’s, as things now appear.”

Now, take a hike!

Again, please provide the date for your post on this board when halozyme was in the low 30’s and you (as you claimed) posted about buying halozyme.

Since I mentioned prices, I went to my brokerage account to check. Of the shares I now own I bought 20% below 34; 40% below 35; and 40% below 38. Not proud of that last 40%. I sold half just below 40 (did not hold to 45 as I first planned to). Those share I bought earlier than the ones I now own, so I probably averaged below 34 for them. “Yeah, right.” Not that it makes much difference, my position in Halozyme is small compared to the old days. With what I have, I am just waiting to go long term. What I sold was short term, unfortunately, but I had had enough.

I see that even the thought of my having bought Halo in the low 30’s upsets you. Tell you what: don’t worry about it, not good for your health. Be happy instead about what you call my “doom and gloom”, which in your mind will be of great benefit to you. Thank me. You used to thank those who were not sufficiently gung-ho, and informed them that you are going to use your inexhaustible funds to buy the shares they would sell. Notice also I am not quoting you, don’t go postal about words I use without attributing them to you. Bad for your health, like I said. It is my impression that when others express doubts, they are “doom and gloom” people. When you indict management it is completely warranted, constructive and an inducement for management to do better. Halozyme’s price is not where I thought it would be by now. My hopes for the stock have changed. Call that whatever you want, it changes nothing. Where I buy and sell the few share that I do, does not make you better or worse off. If you think I am lying, gloat with a contented grin and maintain a superior silence. Like I said, Happy Easter.

Yeah, right! We all believe you. Would you please share to the date of your post when you indicated you were buying some in “low 30’s”? BTW, a retrospective post of saying you bought in 30’s when the stock was already hire would not count.

My prediction of triple digits was incorrect. I own it. It was predicated on three new deals, one of which was supposed to be a major innovation with high-volume auto injector.

This is exactly why I am critical of Halo’s management. They did not deliver on what they projected. You don’t seem to be able to process that an investor can be simultaneously expecting more of a management and yet think that the underlying technology is of a greater value than the market gives it. This is exactly why halo was cheap in low 30’s. The permabears were predicting it was headed to 20’s. It did not.

My point in many of my posts has been that even without new deals, halo was and is cheap. It won’t go to 100’s without new deals, but it can easily reach 50’s and 60’s with existing programs based on it’s PEG , PE ratios, growing profit margin and EBITA.

Hehe. In my gloom and doom I bought at the amazing low 30’s and I so posted at the time. I intended to sell half at around 45. That was not to be, I sold half around 40. I also posted that at the time. I still have half, but my confidence is waning due to my doom and gloom which virtually guarantees a bright new day, by your theorem. By the way, how is that surge to triple digits within a matter of months you forecast more than a year ago coming along? You recently noted that we have a positive DeBarre indicator. Have you made peace in your own mind with the CEO? The IR person, too? I still have some shares and am anxious to benefit. Happy Easter.
PS. I am still absorbing the secrets of how not the make money, which you revealed to me.

Funny. Here's hoping that your're right.

Last time there was a bunch of doom and gloom posts in agreement of each other by our three perma-bears on this board, we rallied from 30’s to 40’s. Prior to 2023, we saw that same phenomenon with the 2 perma-bears. Each time the numbers of their negative posts in agreement with one another went up, we rallied from single digits to teens and teens to 20’s and so on. Let’s welcome this overtly bearish sentiment, it seems to signal a new rally in halo.

It would surprise me if Halozyme management did not leave any room for positive surprises. In that, too, I don’t think I am alone or possess some unique grasp of things.

In general, some vague malaise has got hold of this stock, some foreboding… It is as if Halozyme’s time on top of the hill has come and gone, new know-how and fading patent exclusivity is bringing in new and competent entrants. This is certainly obvious with injectors, (with which Halozyme shot itself in the foot, IMO) but also appears with the emergence of other, alternate modes of subcutaneous delivery. I fear the market doubt is systemic. The argument that new technology is early in its development cycle does not seem successful. There may be some doubt about Halozyme‘s continuing in-house research prowess, or ability to substitute it with acquisition.

On second thought, it is possible that the market thinks those patents will most likely be granted. If so, this is already baked into the current price. My assumption is that they are not at all a sure thing but I could be completely wrong.

On the whole, I agree with you and easycomeandgo. The current PPS reflects all available information and we can assume that no assumptions have been ignored by the institutions that hold the stock. Undoubtedly, the market's main concern is growth beyond 2028. However, I think that the information Halo provided during the presentation in january contained some significant uncertainties, some of them regarding the pending patents. If and when those patents are granted, those uncertainties will be removed and that should alleviate some, certainly not all, of the concern with future growth.

We do have three potential approvals in the next six months or so, Hytrulo for CIDP, Tecentriq and Ocrevus. If they all get approved, that should also help. On the other hand, I don't think the market is particularly excited about any of them. I think investors are concerned that Darzalex was the exception to the rule and that none of the Enhanze products in development will do nearly as well. Of course, some of the products eventually could exceed expectations and the stock price will reflect that. In the meantime, it seems that only substantial new deals and the acquisition of a strong technology platform can restore confidence and really turn things around for Halo.

Halo's YTD performance matches exactly the S&P 500. It's underperformed the S&P 500 at 6 months and 1 year.

https://finance.yahoo.com/quote/HALO/chart?nn=1#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--

I agree that the patents are material to future income, but I believe that this is baked into the current price and we are not going to break out of the range unless there is hope for future growth. This concern over the lack of new deals is taking the place of the patent cliff worries of recent years and will get more prominently featured in analyst papers going forward.

I think that, with almost all shares in professional hands, no possible assumptions go ignored and that the price reflects that. This can be taken for certain after the management presentation on intellectual property durability. This is disquieting. I doubt that elementary analysis based on multiples, etc., is ignored by institutions. There is no scarcity of unfulfilled enthusiastic published research, either. I only hold what I do because it is short term. Probably not the best of reasons. The market seems expensive to me.

Oh, thank you very much for showing me how wealth is not created. I always yearn for such highly regarded pointers on that. Expert is as expert does.

I am assuming that if all patents are granted, Halo gets an additional 7 years of royalties on Tecentriq and possibly 10 years on Hytrulo, plus 3 years without reduction in royalties for Ocrevus. Probably not enough to reach new highs but maybe enough to get to $50, especially if it happens soon. Of course, if no new deals are signed in ‘24, we are in serious trouble. They have already destroyed their credibility, it’s going to be really hard to regain investors’ trust if they don’t deliver something soon.

“Evil”?!!! Who said anything about management being “evil”?!!!

I’m sorry you regularly resort to hyperbole and see everything at such black and white extremes. This kind of emotional thinking is not how wealth is created.

It is perfectly reasonable to ask for more from management when they don’t deliver on certain promises (e.g. 3 deals for 2023). It is also reasonable to lean on them for selling (as opposed to buying some) shares when many including the management opine that the stock is undervalued.

Despite these shortcomings, a reasonable investor can also simultaneously appreciate the underlying successful technology that has made Halozyme highly profitable and a EBITA growth machine.

Just because they failed on a some fronts, it does not make them “evil” or “self-destructive.” It just means they can do better. Even the best C-suites make some mistakes at times. Best case scenario they learn from their mistakes and worst case scenario, investor can push (or at least express a need) for a change in leadership (I for one would be happy with changes). However, none of this makes the management “evil” or the underlying successful technology “un-investable” as you claim.

If you thought this way, you would have missed the recent 30% run from low $30’s to $40 and the previous runs from single digits to all time highs. Some of us were able to see the value of Enhanze despite the management failures in 2023 and loaded up even more in the low 30’s. I wrote on this board that Halozyme is a cash generating machine despite the management (not because of it) and still believe this.

Halozyme will continue to grow EBITA and is undervalued based on the already-approved Enhanze products. The stock will be perform quite well even without new deals. However, some of us (including me) would like to see even more with new deals, insider buys and better communication.

There is no indication when patents will be granted, but I don't think it will move the needle outside of the current rangebound limits at all. By the way, we've reached the end of the quarter with yet another goose egg for new deals. I'm starting to think that we are being actively lied to when HALO trumpets all the interest in partnerships that are supposedly percolating.

Probably not. You can’t blame someone for cashing in stock. It’s not like he’s selling into major strength. He’s not timing this just selling to pick up some cash. Maybe he wants a vacation home. I never look at program insider selling as a major negative. There hasn’t been any insider buying in a long time which concerns me a little bit but the buybacks can be looked at as an indirect way of insider buying I guess.
On another note I think that it takes at least a couple years to integrate an acquisition so we’ll see if it was money well spent soon enough. Certainly looks like it’s been accretive so far not that much.
I’m not a big fan of companies that over hype their stock with BS announcements so lack of announcements doesn’t bother me as much as it does others in this thread. There seems to be a lot of positive stuff going on just not a lot of PR. That being said if you call the company they should call back. No response is not acceptable.

Fantastic tweet from today:

“I ran a screener of

ROIC 3yr Average >20%
FCF margin 3yr Average >15%
Revenue Growth >25%

The top 4 Results were
1) Nvidia $NVDA
(46% / 28% / 125%)
2) Booking Holdings $BKNG
(28% / 28% / 25%)
3)Arista Networks $ANET
(51% / 25% / 33%)
4)Halozyme $HALO
(42% / 47% / 25%)”

I took a closer look at the slides. There is a patent pending for Tecentriq SC, Ocrevus SC and Hytrulo. Have they said when they expect these patents to be granted? If they do get granted, it'll make a significant difference.

It is not for me to reply to your question, it wasn’t addressed to me. Besides, I have no idea of what LaBarre is doing with his 10b-5. I can categorically say that a discussion is not easy. Reading the board, one comes away with the impression that for some unknown reason Halozyme management is intent on subverting the company’s stock, doing all they can, in defiance of its amazing promise, to knock any and all support from under it. They do not respond to belligerent interrogatives, corporate communications has taken upon itself to destroy the place of its employment, as they successfully did with the stellar company Antares. We probably need a resident shrink on the message board to attempt to deal with the persecution complex that rules. After reading the posts, one has to ask oneself, why on earth would I invest money in this thing? Good question, in any case… If management is so evil, why own the stock? Why, indeed…